<DOC>
	<DOCNO>NCT01183013</DOCNO>
	<brief_summary>The primary objective demonstrate superior glycaemic control ( HbA1c reduction ) 30 week linagliptin/pioglitazone ( 5/15 , 5/30 5/45 mg ) versus respective individual monotherapies pioglitazone ( 15 mg , 30 mg , 45 mg , administer orally daily ) , linagliptin ( 5 mg , administer orally daily ) . In addition , durability treatment effect safety chronic treatment condition investigate .</brief_summary>
	<brief_title>30 Week Parallel Group Comparison Study Linagliptin + Pioglitazone ( 5+15 , 5+30 5+45 mg ) qd Versus Respective Monotherapies , Followed Comparison 5mg+30mg 5mg+45mg Versus Respective Monotherapies Type 2 Diabetes 54 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis type 2 diabetes mellitus prior inform consent 2 . Male female patient insufficient glycaemic control ( HbA1c &gt; = 7.0 &lt; = 10.5 % Visit 2 ) diet exercise alone , without oral antidiabetic drug therapy within 10 week prior start runin period ( date Visit 2 ) 3 . Age &gt; = 18 &lt; = 80 year start date Visit 1 ( Screening ) 4 . BMI &lt; = 45 kg/m2 ( Body Mass Index ) start date Visit 1 ( Screening ) 5 . Signed date write informed consent start date Visit 1 accordance GCP local legislation Exclusion criterion : 1 . Uncontrolled hyperglycaemia confirm glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/l ) overnight fast screen placebo runin period ( cf . Section 3.3.4.1 ) 2 . Myocardial infarction within 6 month , stroke TIA within 3 month prior inform consent 3 . Clinical evidence active liver disease ( e.g . jaundice ) ALT level &gt; 2.5 time upper limit normal ( accord pioglitazone label ) 4 . Bariatric surgery , perform within past 2 year prior inform consent plan time inform consent 5 . Gastrointestinal surgery prior inform consent induce chronic malabsorption 6 . Known hypersensitivity allergy investigational product ( linagliptin and/or pioglitazone ) excipients ( include match placebo ) 7 . Contraindications pioglitazone defined local prescribe information ( SPC ) , particularly : Diagnose heart failure history heart failure Haemodialysis patient , due limit experience pioglitazone 8 . Treatment gemfibrozil , montelukast , trimethoprim , rifampicin accord pioglitazone label respective restriction Section 4.2.2 9 . Treatment rosiglitazone , pioglitazone , GLP1 analogues , insulin within 3 month prior inform consent 10 . Treatment antiobesity drug ( e.g . sibutramine , orlistat ) 3 month prior inform consent 11 . Alcohol drug abuse within 3 month prior inform consent history alcoholism 12 . Current treatment systemic corticosteroid time informed consent change dosage thyroid hormone within 6 week prior inform consent 13 . Participation another trial investigational drug within 30 day prior inform consent 14 . Any clinical condition judge investigator would allow safe completion protocol , e.g . inability patient comply study procedure 15 . Premenopausal woman ( last menstruation &lt; = 1 year prior informed consent ) : nursing pregnant childbearing potential ( i.e . permanently sterilise ) practice highly effective method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . A highly effective method birth control define accord Note Guidance nonclinical safety study conduct human trial pharmaceutical ( CPMP/ICH/286/95 , modification ) result low failure rate ( i. e. le 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , hormonal intrauterine devices/systems ( IUDs/IUSs ) , sexual abstinence vasectomise partner 16 . Symptomatic gallbladder disease last six month 17 . Medical history pancreatitis . 18 . Patients urinary bladder cancer history urinary bladder cancer uninvestigated macroscopic haematuria 19 . Any contraindication restriction use pioglitazone accordance local prescribe information pioglitazone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>